Last reviewed · How we verify
sasanlimab
At a glance
| Generic name | sasanlimab |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Monoclonal antibody |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma (PHASE2)
- A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer (PHASE1)
- A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies (PHASE1)
- Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies (PHASE1, PHASE2)
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
- A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer (PHASE1)
- Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) (PHASE1, PHASE2)
- A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sasanlimab CI brief — competitive landscape report
- sasanlimab updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI